<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Ortiz de la Rosa, José Manuel</dc:creator>
  <dc:creator>Nordmann, Patrice</dc:creator>
  <dc:creator>Poirel, Laurent</dc:creator>
  <dc:date>2019-07-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">To evaluate the efficacy of the recently launched β-lactam/β-lactamase inhibitor  combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL- producing Escherichia coli and Pseudomonas aeruginosa strains.Methods: A series of  ESBL-encoding genes (blaTEM, blaSHV, blaCTX-M, blaVEB, blaPER, blaGES and  blaBEL) was cloned and expressed in E. coli or P. aeruginosa recipient strains.  Cultures of E. coli TOP10 harbouring recombinant plasmids and therefore producing  the different ESBLs tested were grown in order to perform measurements of catalytic  activities, using benzylpenicillin, ceftazidime and ceftolozane as substrates. IC50s  were additionally determined for clavulanic acid, tazobactam and avibactam.Results:  We showed here an overall better activity of ceftazidime/avibactam compared with  ceftolozane/tazobactam toward ESBL-producing E. coli and P. aeruginosa. Several  ESBLs of the GES, PER and BEL types conferred resistance to  ceftolozane/tazobactam in E. coli and P. aeruginosa. For GES-6 and PER-1  producers, resistance to ceftolozane/tazobactam could be explained by a high  hydrolysis of ceftolozane and a low activity of tazobactam as an inhibitor. On the other  hand, PER-producing P. aeruginosa also exhibited resistance to  ceftazidime/avibactam.Conclusions: Altogether, the results show that the ESBL PER- 1, which is widespread worldwide, may be a source of resistance to both  ceftolozane/tazobactam and ceftazidime/avibactam. Excellent activity of  ceftazidime/avibactam was highlighted for both ESBL-producing E. coli and ESBL- producing P. aeruginosa.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/307940</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307940/files/nor_erc.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307940/files/nor_erc_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkz149</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Journal of Antimicrobial Chemotherapy. - 2019, vol. 74, no. 7, p. 1934–1939</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
